|
Drug name | Tumor type | Mechanism of action for ROS induction | References |
|
Actinomycin D | Sarcomas; Wilms’ tumor; testicular; melanoma; neuroblastoma; germ cell; retinoblastoma; choriocarcinoma | Inhibition of Bcl-2 | [179] |
|
Bleomycin | Melanoma; Hodgkin’s and non-Hodgkin’s lymphomas; testicular; head and neck; cervical; malignant pleural effusions | Formation of Fe(II)-bleomycin-DNA complex that is oxidized by O2 | [185, 187] |
|
Busulfan | Chronic myeloid leukemia | GSH depletion and NOX activation | [182, 183] |
|
Carmustine | Brain; Hodgkin’s and non-Hodgkin’s lymphoma; melanoma; myeloma | GSH depletion via inhibition of GR | [169] |
|
Cisplatin | Ovarian; colon; testicular; germ cell; bladder; lung; head and neck | Increased expression of p47 subunit of NOX | [17, 188] |
|
DMAT | Prostate | Inhibition of CK2 activity | [173] |
|
Doxorubicin | Hodgkin’s and non-Hodgkin’s lymphoma; leukemia; breast; gastric; neuroblastoma; ovarian; lung; soft tissue and bone sarcomas; thyroid; bladder | p53-dependent transcription of cytochrome oxidase 2; FOXO3-dependent transcription of Noxa and BIM; quinone metabolism | [190] |
|
Etoposide | Lymphomas; leukemias; neuroblastoma; breast; lung; testicular; gastric | FOXO3 dependent transcription of Noxa and BIM | [188, 190] |
|
5-Fluorouracil | Gastric; colon; gynecological; breast; head and neck; lung; skin | p53-dependent transcription of ROMO 1 | [188, 189] |
|
Gemcitabine | Pancreatic; lung; in combination with other drugs: breast, bladder, and ovarian | Activation of AKT and ERK 1/2 which leads to upregulation of CXCR4 | [198] |
|
Mitomycin C | Colon; breast; head and neck; bladder; cervical; gastric; pancreatic; liver | Inhibition of Bcl-2 | [180, 202] |
|
Paclitaxel | Ovarian; breast; non-small cell lung carcinoma; Kaposi’s sarcoma | Activation of Rac1 subunit of NOX; disruption of the mitochondrial membrane | [177, 178] |
|
Tamoxifen | Breast | Inhibition of CK2 activity | [175] |
|